Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Fear not holy man. The target will rise in line with the consolidation.
Forgive me if this point has been raised before but I have been on holiday for 2 weeks. As the shares are going to be consolidated up i.e. 1 for 100 then obviously the market value will be more. However AR had a clause for options when the share price hit 0.5p?? I believe. Clearly it should now do this or very quickly. Does that mean that he can now exercise his options? Can someone please confirm or otherwise. I have been a holder for some time and let us hope that this reverse takeover works for all of us long suffering shareholders. Thanks in advance. revshep
There a shell that did a reverse take into Premaitha & have a new director,the clown who was in charge is gone. Premaitha Health is a molecular diagnostics company employing next generation DNA analysis technology to develop, manufacture and sell molecular diagnostic products intended to have a major beneficial impact on human health. Premaitha is responsible for the development, manufacture and commercialisation of their diagnostic products and works with partners to provide the instrument platforms needed by its laboratory customers. Premaitha Health was established in 2013 and is located on Manchester Science Park, Manchester, UK. Premaitha’s first product is the IONA® test which is the first CE marked non-invasive in vitro diagnostic product for prenatal screening. The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha’s clinical laboratory customers to perform the test in their laboratory, using existing clinical workflow. A fundamental element of the IONA® test is exceptional technical support and customer service. The IONA® test is non-invasive, simple and accurate, and is designed to encourage the broad uptake of the technology allowing all pregnant women accurate and safe information about their pregnancy. Premaitha is built upon a wealth of diagnostic expertise with an experienced management team, scientific and technical excellence and class leading quality management and development systems. Currently focused in the area of non-invasive prenatal tests (NIPT), Premaitha aims to extend its portfolio to cover oncology, personalised medicine and other areas of human health.
Thanks MB honest post (recommended) SO worth a punt ??
Very little in all the years I've been invested with them ! This is a new start and new company, which is looking very promising.
Good morning everyone, could you guys tell me what viy do ?
Could not agree with your more Ian. However with them attending World Congress they will create more interest & they will no doubt release news how it went some time this week. There is no doubt shareholders will vote in favour of the new deal,after all i doubt any of of who bought in did not buy because of the deal.
interest in the product? id say its a nailed on certainty that Adam reynolds and the bod fully explored the market and spoke to the 600 labs who would become Premaithas customers. They are not buying premaitha on a punt. There is a real need for the service to rival the current system of sending bloods to the usa labs and waiting 16 days for a turn around on result. its not if but when the sp rises to match the potential. might be after the vote this thursday when its official.
Could get news some time this week if they get some interest in there product. 13th World Congress on Fetal Medicine, Nice, France. 29th June – 3rd July 2014. Premaitha is exhibiting at the 13th World Congress on Fetal Medicine. So please visit us on Stand No.1.
Premaitha Health’s executive management team is led by Dr Stephen Little, a successful serial biotechnology entrepreneur who has a proven diagnostic and commercial track record. He has assembled similarly talented and experienced team of individuals with the skills, knowledge and background needed to bring a prenatal screening product to market. Commenting on today’s news, Dr Stephen Little CEO at Premaitha Health said: “Our approach is to take early stage discoveries and translate them into clinically useful diagnostic products that can be widely used to benefit human health. As we build and commercialise the IONA® test, we are not only building a valuable in vitro diagnostic product in its own right but also establishing a template for creating valuable diagnostic content on third parties’ next generation sequencing systems.” Dr Little added: “The global market for prenatal testing is estimated at $4.2 billion and this is an exciting phase in our development of the business roll-out so we are looking forward to working with the new team and delivering on our plans for the IONA® test.” The technology used in the IONA® test will be new to many potential customers. Premaitha is in the process of establishing a demonstration laboratory at its Manchester headquarters. This laboratory will reproduce the complete IONA® Test workflow so that customers can test their own samples and be trained in the process. The highly qualified team of scientists and technicians at Premaitha are also currently undergoing IONA® Test development and design verification processes; target completion for this stage is by 30 September 2014. The clinical performance and commercialisation testing is then anticipated to be substantially complete by 31 December 2014 with expected commercial launch of the IONA® test to commence January 2015. The targeted customers for the IONA® test are the estimated 600 laboratories offering prenatal screening within the EMEA region as well as similar labs throughout the rest of the world. Premaitha’s primary channel to market will be through its own direct sales force targeting laboratory directors supported by activities to target and gain support of key opinion leaders. Following the initial launch in Europe, it is the intention to extend sales and marketing activities in to Asia. ENDS Media Enquiries: Fiona Tooley, TooleyStreet Communications Fiona@tooleystreet.com or M: 07785 703 523 For further information: read about us at www.premaitha.com or call +44 (0)161 667 6865 or email us on info@premaitha.com: :Visit our stand at the 13th World Congress in Fetal Medicine 29 June to 3 July 2014 Nice, France http://fetalmedicine.org/fmf-world-congress-1 Premaitha to join AIM and launch exciting NIPT to improve prenatal screening globally UK: Friday 13 June 2014: Molecular Diagnostics Company, Premaitha Health , based in Manchester’s
This shows the need for early detection, as taken from Support Organisation for Trisomy 13/18: PATAU’S AND EDWARDS’ SYNDROMES Trisomy 13 was named Patau’s Syndrome after the doctor who identified the chromosomes responsible in 1960, and trisomy 18 or Edwards’ syndrome was named after Dr John Edwards for the same reason. Trisomy 13 and 18 births occur about once in every 1,800 pregnancies and are the most common autosomal trisomies after trisomy 21, which is also known as Down syndrome. Trisomy 13 affects equal numbers of boys and girls whereas babies with trisomy 18 are three times more likely to be girls. In the 12 months April 2008 to April 2009 there were 172 diagnoses of Patau’s and 495 diagnoses of Edwards’ syndrome. 91% of Patau’s and 92% of Edwards syndrome diagnoses were made prenatally, and 65% of Patau’sand 68% of Edwards’ pregnancies were terminated. It is estimated that there were 18 live births with Patau’s syndrome and 37 live births with Edwards’ syndrome. (National Down Syndrome Cytogenetic Register Annual Reports 2008/09 - data are provisional).
havent a clue what that means but i suspect (strongly) that all charts are out of the window due to the fact vialogy is about to become a completely new and different company.
I'd never heard of Patau Syndrome until I read your post. What a hideous and terrible genetic fault. Very distressing.
Your not missing anything old bean. The more we have all researched and shared it's a complete no brainer. All the ducks are lining up ... I think we were all disappointed initially, wanting - naively in hindsight - a spike. This will get to the prices I wanted it to spike to but in a slightly different timeframe. Reynolds was voted one of the top 50 business men, has put a great deal of his own money in and has set targets of 50p equivalent. I have zero doubt that it will get there. As previously discussed competition is not an issue as we are not looking to displace them!!!! As soon as people grasp that then the model becomes a thing of beauty - plus economies of scale will kick in going forward and it will grow exponentially! NHS entry as alluded to by both the Financial Times and The Telegraph would be the icing on the cake. If anyone wants me to PM them a summary of conversations with VIY then PM me and I will reply.
simple and to the point van... surely the point of the test is to establish the likelihood of a lady carrying a downs child. Time is then of the essence as a decision then has to be made as to whether to terminate the pregnancy? or am i missing something. the difference in a 2 day turn around to 16 days is massive and critical.
Thanks for finding it and 188 it is - case closed ;-)
yes i have ,just been reading the rns again it was actually 95.4m shares issued not 59m (thats in teh eraly part of teh rns as a placing. heres the original post you mentioned Current sp of 0.5p and sp of 50p after rto are not equal equations From current mid of 0.15p sp needs to rise around 340% to trigger 0.5p options Mcap £13.2M at 0.5p And Mcap after rto and dilution shares placed and sp of 50p is £94M with 188M shares in issue, 712% higher than the Mcap pre rto and dilution and at 0.5p, which is £13.2M. Technically his 0.5p options would convert at 7p if we are to align the current and new Mcaps Not sure if anyone worked out than shareholdings are diluted x7 or 700%))) Current shares in issue 2.689Bn, consolidation of 1for100 gives 26.89M shares in issue pre rto amd dilution. Shares in issue after rto and dilution 188M 188M/26.89 = 6.99
Haven't you missed the......... Acquisition of "Premaitha" satisfied through issue of 95M new shares at 11p Open offer of up to 6.7M new shares of 11p
it seems to me 26.89+95+59+6.7 = 187.6m so broadly iro of tailored 188,163,709 I quoted, as I can't find that posting, which may be effected by including options. .
that doesnt tally up but i do recall the post detailing it. current shares = 2689 m which after consolidation is 26.89m new shares 59,090,909 not sure if the new shares are to be consolidated ? i cant see it as they are issued at 11p so already "consolidated" so thats 26.89m original shares plus 59m new shares total shares approx 86 million.giving rough mcap at 0.50p of £43m if the figure you quote of 188m shares is right (i dont thing it is) then thats a massive mcap of £92m at 50p
I've said this before but it's simple. Lab a) takes up the Iona test with sharper profits and a 2 day turn around. Lab b) doesn't, sticks with a 14/16 days time frame. Lab b) will lose business. End of.
Here's the calc which I think was amended to include options to 188mn..... Current shares in issue 2689Bn 26.89M after 100/1 consolidation Acquisition of "Premaitha" satisfied through issue of 95M new shares at 11p Placing of 59M new shares at 11p Open offer of up to 6.7M new shares of 11p 95+59+6.7/ 158.7M new shares at 11p
The IONA® test will be available as a CE marked product for use in clinical laboratories from January 2015. Premaitha is currently in discussions with laboratory customers and advising them on how to be one of the first clinical laboratories across Europe to offer this test to pregnant women.
I'll sell mine at 450% when it gets to 50p.
total shares in issue will be 188,163,709. It's also been detailed here a week+ or so ago from memory